7U5.F BIOTON S.A. ZY 20

Healthcare Biotechnology Frankfurt Exchange
0.7560 EUR
Close of Nov 11, 2026
0.7210 1.04
Market cap
EUR 64.9M
P/E
-
P/B
0.49x
ROE
-4.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7U5.F undervalued?

Graham number

The Graham number of BIOTON S.A. ZY 20 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOTON S.A. ZY 20 fundamental analysis

No fundamental analysis for BIOTON S.A. ZY 20 yet.

BIOTON S.A. ZY 20 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOTON S.A. ZY 20

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diabetic drugs.BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

Full company profile